MARKET

EDIT

EDIT

Editas Medicine Inc
NASDAQ
2.430
+0.065
+2.75%
Pre Market: 2.460 +0.03 +1.23% 09:20 12/05 EST
OPEN
2.350
PREV CLOSE
2.365
HIGH
2.490
LOW
2.327
VOLUME
2.65K
TURNOVER
--
52 WEEK HIGH
4.537
52 WEEK LOW
0.9101
MARKET CAP
237.21M
P/E (TTM)
-1.0231
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at EDIT last week (1124-1128)?
Weekly Report · 4d ago
Editas (EDIT) Q2 2024 Earnings Call Transcript
NASDAQ · 11/27 23:13
NVO Stock Down as Rybelsus Misses Goals in 2 Alzheimer's Studies
NASDAQ · 11/25 16:10
Biogen Inks Research Deal With Dayra to Boost Immunology Pipeline
NASDAQ · 11/25 15:43
Weekly Report: what happened at EDIT last week (1117-1121)?
Weekly Report · 11/24 09:09
COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know
NASDAQ · 11/20 16:38
Top 3 Genomics Stocks to Consider for Your Portfolio
NASDAQ · 11/18 13:48
Weekly Report: what happened at EDIT last week (1110-1114)?
Weekly Report · 11/17 09:09
More
About EDIT
Editas Medicine, Inc. is a genome-editing company developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms and foundational intellectual property for both CRISPR systems. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. It is engaged in discovering, developing, manufacturing, and commercializing durable, precision in vivo gene-editing medicines for a broad class of diseases. Vivo medicines include vivo editing of hematopoietic stem cells (HSCs), liver cells and other tissues. Vivo gene editing in HSCs supports the advancement of research programs to treat non-malignant hematological diseases.

Webull offers Editas Medicine Inc stock information, including NASDAQ: EDIT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EDIT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EDIT stock methods without spending real money on the virtual paper trading platform.